secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116254
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell Nasdaq delisting risk: MVLS below $35M minimum
--------------------------------------------------------------

- Received Nasdaq deficiency notice on Nov 6, 2023 for MVLS below $35M required for continued listing.
- Has 180 calendar days, until May 6, 2024, to regain compliance; must close at $35M+ for 10 consecutive days.
- Common stock continues trading under symbol BCLI on Nasdaq Capital Market during compliance period.
- Company intends to take reasonable measures to regain compliance but no assurance of success.
- If not compliant by May 6, 2024, Nasdaq may delist; appeal possible but uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923116254/0001104659-23-116254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923116254/tm2330353d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer